港股異動 | 石藥集團(1093.HK)一度大漲超10% 簽訂腫瘤產品授權及商業化協議
格隆匯3月10日丨石藥集團(1093.HK)盤初曾直線拉昇至超10%,現報8.85港元,漲幅收窄至6.37%,總市值1060億港元。石藥集團簽訂腫瘤產品授權及商業化協議,於中國進行商業化活動,並擁有商業化授權的優先談判權。同時,集團同意向倍而達藥業方面進行股權認購,首次認購金額2億人民幣。另外,中泰料石藥2020年四季度業績將持續回暖,維持10.84港元目標價。公司將於年報後積極推進回科創板上市工作,如能成功將夯實資金實力。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.